Eli Lilly and Company (TSX:LLY)

Market Cap	1.25T +17.1%
Revenue (ttm)	89.37B +44.7%
Net Income	28.30B +94.9%
EPS	31.47 +96.0%
Shares Out	n/a
PE Ratio	44.05
Forward PE	29.43
Dividend	0.22 (0.61%)
Ex-Dividend Date	Feb 13, 2026

Volume	8,793
Average Volume	30,584
Open	36.89
Previous Close	36.93
Day's Range	36.56 - 37.02
52-Week Range	22.85 - 41.00
Beta	n/a
RSI	46.51
Earnings Date	Feb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 50,000
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.

Financial numbers in USD